Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs). We aimed to assess AZA’s effectiveness regarding relapses, disability progression, time to the first relapse, magnetic resonance imaging (MRI) activity, and safety compared with other approved first-line DMTs in an Indian population in a real-world setting. We conducted a single-center prospective study of treatment-naive RRMS patients between 2017 and 2019. We evaluated the effects of AZA and other approved DMTs on clinical and radiological measures. Among 192 eligible patients (F:M ratio 2.84:1), 68 patients (35.4%) were on AZA, 68 patients (35.4%) were on dimethyl fumarate (DMF), 32 patients (16.7%) on interferon (IFN beta-1a), and 16 patients (8.3%) on teriflunomide (TFL). Four treatment groups were comparable: AZA v/s DMF v/s TFL v/s IFN beta-1a. In primary outcomes, there was no significant difference between the groups in terms of change in the Expanded Disability Status Scale (EDSS) score at three months (p-value = 0.169), six months (p-value = 0.303), 12 months (p-value = 0.082), and 24 months (p-value = 0.639), the number of relapses (p-value = 0.229), and time to the first relapse (p-value > 0.05 in all groups). In the secondary outcome, there was no significant difference between the treatment groups on serial MRI parameters used according to “Magnetic Resonance Imaging in Multiple Sclerosis” (MAGNIMS) 2016 criteria (p-value > 0.05). In safety outcomes, leukopenia was significantly more common in the AZA group (p-value = 0.025), flu-like symptoms (p-value = 0.0001), and injection site reactions (p-value = 0.035) were significantly more common in the IFN beta-1a group. Our study suggests AZA is as effective as other approved DMTs and a good alternative as a first-line treatment for multiple sclerosis’s clinical and radiological activity in real-world settings on short follow-up. Based on these results, more randomized controlled trials of AZA v/s DMF or other DMTs are needed for more robust outcomes.
Background and Objectives: Cerebral venous thrombosis (CVT) accounts for <0.5%–3% of all strokes but is increasingly identified with the availability of advanced imaging. Standard anticoagulation therapy is effective in most cases; however, a subset of patients experience clinical deterioration despite optimal medical management. Endovascular treatment (EVT) has emerged as a potential rescue therapy, though evidence remains limited due to the absence of randomized controlled trials. We aimed to evaluate the efficacy and safety of EVT in severe, medically refractory CVT cases at a tertiary care center in central India. Methods: This prospective study included 36 patients with severe CVT who underwent EVT over 30 months. Procedures included catheter-directed thrombolysis, mechanical thrombectomy, and balloon venoplasty. Clinical features, procedural details, and outcomes were recorded. Post-procedure outcomes were assessed using the modified Rankin Scale (mRS) at 3 months. Results: During the study period, out of the total cases of CVT presented to our center, 22.7% underwent endovascular thrombectomy. Of the 36 patients, 89.3% were male, and the majority were younger than 30 years. Headache was a universal presenting symptom, followed by seizures (75%) and focal neurological deficits (58.3%). All patients underwent balloon venoplasty; 35% received adjunctive thrombolysis, and 21% underwent aspiration thrombectomy. Technical success was achieved in all cases. Median mRS improved significantly from 3.0 at baseline to 1.0 at 3 months ( P < 0.001). No major complications occurred. Right sigmoid sinus thrombosis was significantly associated with complications ( P = 0.041). Conclusions: EVT is a safe and effective rescue option for patients with CVT refractory to standard anticoagulation, leading to substantial neurological recovery. Larger multicenter studies are needed to refine patient selection and standardized treatment protocols.
6 April 2023 in Annals of Indian Academy of Neurology